Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
May 10 04:00PM ET
35.65
Dollar change
-0.52
Percentage change
-1.44
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y-3.79% Shs Outstand Perf Week-3.38%
SponsorPrincipal Financial Services ETF Type Tagsequity Return% 3Y-11.70% Total Holdings270 Perf Month-4.23%
Fund Family Bond Type Tagshealthcare Return% 5Y2.02% AUM38.72M Perf Quarter-4.59%
Index- Average Maturity Tagspharmaceutical Return% 10Y NAV% Perf Half Y28.49%
Index Weighting Commodity Type Tagsbiotechnology Return% SI NAV/sh Perf Year-3.79%
Active/Passive Quant Type Tagsinnovation Flows% 1M-8.07% 52W Range25.66 - 39.75 Perf YTD-1.86%
Dividend TTM- ESG Type Tags- Flows% 3M-18.30% 52W High-10.30% Beta1.00
Dividend Ex-DateDec 29, 2021 Dividend Type Sector/Theme Flows% YTD-20.73% 52W Low38.95% ATR (14)0.61
Expense0.42% Structure Type Region Flows% 1Y RSI (14)48.04 Volatility0.53% 0.94%
Option/ShortNo / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.67 Prev Close36.17
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume5.27K Price35.65
SMA201.32% SMA50-2.58% SMA2006.09% Trades Volume3,555 Change-1.44%
Jan-26-22 09:38AM
May-12-21 04:45PM
12:00PM
Aug-20-20 05:25PM
Jul-16-20 04:51PM
01:41PM Loading…
Dec-18-19 01:41PM
Dec-02-19 02:40PM
Oct-23-19 10:10AM
Sep-03-19 05:46PM
Jun-24-19 04:23PM
Apr-11-19 03:33PM
Apr-05-19 08:00AM
Apr-02-19 10:00AM
Mar-12-19 11:05AM
Mar-04-19 11:05AM
01:00PM Loading…
Feb-28-19 01:00PM
Feb-27-19 03:00PM
Feb-14-19 10:05AM
Jan-24-19 01:00PM
Mar-01-17 08:59AM
Aug-31-16 09:00AM
Aug-25-16 10:55AM
Aug-23-16 04:04PM
Aug-22-16 04:15PM
12:05PM
Principal Healthcare Innovators ETF seeks long-term growth of capital. Under normal circumstances, the fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies in the healthcare sector. It invests significantly in early-stage companies within the healthcare equipment and supplies, pharmaceuticals, biotechnology, and life sciences industries that are not yet consistently profitable.